Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtaiBeckley Inc. (NASDAQ: ATAI) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. AtaiBeckley, a clinical-stage biopharmaceutical and biotechnology company focused on mental health treatments, uses SEC reports to disclose material events, financing activities, corporate transactions and updates related to its clinical pipeline.
Investors researching ATAI can review current and historical filings such as Form 8-K reports that describe significant developments. Recent 8-K filings have addressed topics including the completion of the acquisition of Beckley Psytech Limited and the resulting name change to Atai Beckley N.V., public offerings of common shares to fund clinical programs, FDA Breakthrough Therapy designation for BPL-003 in treatment-resistant depression, and the redomiciliation process that led to AtaiBeckley Inc. becoming a Delaware corporation. Other filings detail shareholder votes on the Beckley Psytech transaction and redomiciliation, as well as prospectus supplements related to registered offerings and resales.
Through this page, users can also locate references to AtaiBeckley’s financial reporting, such as earnings press releases furnished on Form 8-K, and legal or transactional documents filed as exhibits, including share purchase agreements and underwriting agreements. These materials help explain how AtaiBeckley finances the development of its key programs BPL-003, VLS-01 and EMP-01 and how it structures its corporate operations.
Stock Titan enhances the ATAI filings page with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the SEC’s EDGAR system ensure new AtaiBeckley filings appear promptly, while dedicated sections make it easier to find items such as current reports, registration statements and, when available, insider transaction reports on Form 4. This combination of raw filings and AI-generated insights can support deeper due diligence on AtaiBeckley’s regulatory and financial disclosures.
Form 4 filing overview: On 06/27/2025 ATAI Life Sciences N.V. (symbol: ATAI) reported a change in beneficial ownership by Christian Angermayer, who is both a Director and 10% owner.
Key transaction: On 06/26/2025 the insider received a stock option covering 103,000 common shares at an exercise price of $2.25 per share. The award was coded "A" (grant or award) and is held directly by the reporting person.
Vesting & expiration: The option vests on the earlier of (i) the day before ATAIs next annual shareholder meeting or (ii) 06/26/2026, and it expires on 06/26/2035. No deemed execution date or other conditions were noted.
Post-transaction holdings: Following the grant, Mr. Angermayer beneficially owns 103,000 derivative securities (stock options). Table I shows no non-derivative share acquisitions or dispositions.
Investor take-away: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale, so it carries limited immediate signalling value. The award incrementally increases potential dilution but has no direct impact on ATAIs cash position or current share count.